Psilera, a biopharmaceutical company developing next-generation mental health treatments for take-home use, announces the selection of their lead clinical candidate, PSIL-006.
With years of experience in developing cannabinoid medicines, Australia-based MGC Pharmaceuticals will now be branching into psychedelic medicine development.
The first patient has now been dosed in IntelGEnx and atai Life Sciences’ Phase 1 clinical trial to investigate buccal VLS-01 – a buccal film containing...
Cybin has entered into an agreement with Mindset Pharma to acquire an exclusive license to an extensive, targeted class of tryptamine-based molecules.
Awakn Life Sciences has signed the twelve month option agreement with a drug development company that will see its ketamine formulation and route of administration optimised...
Enveric Biosciences has made advancements with its drug discovery and development progress targeting mental health indications and intellectual property (IP).
Dalriada will be leveraging atai Life Science’s newly launched Invyxis platform to establish and rapidly advance a pipeline of new chemical entities (NCEs) in mental health.
Mindset Pharma says its next-generation psilocybin compounds could change the paradigm of microdosing by limiting the psychedelic effect.
An international patent application has been filed by Mindset Pharma Inc.
A quantum drug development programme has been launched by psychedelic healthcare company PsiloThera.